Multiple sclerosis represents an autoimmune-driven neurodegenerative condition affecting the central nervous system, marked by inflammatory demyelination and axonal severance. Positioned as a leader in rare disease diagnostics, our company boasts an exceptional fusion of state-of-the-art technologies and a committed cadre of specialists. We provide a comprehensive range of solutions for multiple sclerosis diagnostics including IVD products, point-of-care testing, and companion diagnostic development services.
Overview of Multiple Sclerosis
Multiple sclerosis stands as the most prevalent acquired demyelinating disorder affecting the central nervous system. Globally, it is estimated to impact over 2.5 million individuals and is recognized as a leading cause of disability, particularly among young adults. The distribution of multiple sclerosis prevalence varies significantly, sometimes reaching up to 10 new cases per 100,000 people.
The pathogenesis of multiple sclerosis involves an inflammatory response involving various cell types such as T cells, B cells, activated microglia, and macrophages, leading to demyelination. Concurrently, processes induced or mediated by inflammation, like oxidative stress resulting in mitochondrial damage, contribute to neurodegeneration.
Fig.1 Disease-modifying therapeutics in multiple sclerosis. (Pérez, C. A., et al., 2023)
Biomarkers Development for Multiple Sclerosis
A defining feature of multiple sclerosis-specific alterations in cerebrospinal fluid (CSF) is the identification of oligoclonal bands (OCB), present in the majority of multiple sclerosis individuals but posing logistical challenges. Potential biomarkers in blood, CSF, and other bodily fluids hold promise for aiding in the diagnosis and monitoring of multiple sclerosis, offering insights into disease activity and progression. Here are some key biomarkers related to multiple sclerosis across different categories:
Cytoskeletal Proteins
Elevated levels of cytoskeletal proteins like neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) in CSF and blood signal are the key indicators of multiple sclerosis advancement.
Cytokines
Cytokines such as interleukins and osteopontin (OPN) levels have been associated with disease severity and progression, showing potential as valuable biomarkers for multiple sclerosis diagnosis.
Autophagy Markers
Autophagy, vital for cellular balance, has been implicated in neurodegenerative diseases. ATG5, ANT1, PINK1, and Parkin are under early investigation as potential diagnostic markers for multiple sclerosis.
Other Biomarkers
Other Biomarkers such as chitinase-3-like protein 1 (CHI3L1), extracellular vesicles (EVs), Anti‑KIR4.1 antibodies, and endothelial factors have shown potential relevance to disease mechanisms.
IVD Kits for Multiple Sclerosis
| Kits |
Applications |
Method of detection |
| OCB ELISA Kit |
Quantitatively detect OCB in samples such as serum, plasma, and related fluids |
ELISA |
| Free Light Chains Kappa and Lambda ELISA Kit |
Quantitatively measurement of human immunoglobulin free light chains kappa and lambda |
ELISA |
| OCB Detection Kit |
In vitro detection of OCB in cerebrospinal fluid or serum |
Isoelectric focusing (IEF) with IgG immunoblot detection |
| Cerebrospinal Fluid IgG Assay Kit |
Quantitative detection of IgG content in human urine and cerebrospinal fluid in vitro |
Turbidimetric inhibition immunoassay (TIIA) |
Our Services
Dedicated to precision diagnostics, we harness cutting-edge genetic testing and groundbreaking biomarker analysis to offer advanced services for the development of IVD products tailored for multiple sclerosis. Additionally, we deliver point-of-care testing and companion diagnostic development services to ensure precise and prompt diagnoses for individuals with multiple sclerosis.
Our commitment to research and development guarantees that we remain at the forefront, consistently enhancing our diagnostic approaches and integrating the newest findings in the industry. Rely on our expertise and experience to provide diagnostic precision, promoting the creation of personalized therapeutic strategies.
If you are interested in our services, please feel free to contact us for more information.
Reference
- Pérez, Carlos A et al. "Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis: A Clinical Update." Neurologic clinics 41.1 (2023): 87-106.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
